Publications by authors named "Mario Lopez Contreras"

Claim this Profile
R
Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.
Ricardo Rosales, Mario López-Contreras, Carlos Rosales, Jose-Roberto Magallanes-Molina, Roberto Gonzalez-Vergara

Hum Gene Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.
Antonio Albarran Y Carvajal, Alfonso de la Garza, Benitez Jose Cecilio Cruz Quiroz, Eduardo Vazquez Zea, Ismael Díaz Estrada, Mario López Contreras

BioDrugs· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
Carlos Manuel Corona Gutierrez, Alberto Tinoco, Tania Navarro, Mario López Contreras, Roberto Risco Cortes

Hum Gene Ther· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus.
Carlos Manual Corona Gutierrez, Alberto Tinoco, Mario López Contreras, Tania Navarro, Patricia Calzado

Hum Gene Ther· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis